SELLAS 总裁兼首席执行官 Angelos Stergiou 医学博士、理学博士表示：“继上个月获得儿童急性淋巴细胞白血病认定之后，我们再次获得儿科罕见病认定，这是对 SLS009 改善患者（包括 AML 儿童）生活的全新转化治疗潜力的又一认可。

Moleculin Biotech ( (MBRX)) just unveiled an announcement. Moleculin Biotech has revealed promising findings showcasing Annamycin’s potential to combat acute myeloid leukemia (AML) resistant to ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Moleculin Biotech ( (MBRX)) has ...

Health care providers now recognize that determining treatment intensity requires careful evaluation of multiple patient factors beyond chronological age, including physiologic function, social ...

Ziftomenib showed significant efficacy in relapsed/refractory NPM1-mutant AML, achieving deep, durable responses in the KOMET-001 trial. The trial enrolled 92 patients, with 23% achieving complete ...

Panelists discuss how the greatest unmet needs include addressing poor outcomes in specific subsets like TP53-mutant disease, ...

The Company has submitted a supplemental New Drug Application (sNDA) seeking the approval of revumenib for the treatment of R/R mNPM1 AML. The sNDA has been granted Priority Review by the FDA and ...

With a new four-year, $1.3 million grant from the U.S. Department of Veterans Affairs, researchers at Case Western Reserve University are investigating a new approach to treat Acute Myeloid Leukemia ...

Results of a recently published long-term follow-up of the ASAP trial, which was conducted at universities and clinics across ...

What Is Acute Myeloid Leukemia? Acute myeloid leukemia (AML) is a type of blood cancer. It starts in your bone marrow, the soft inner parts of bones. AML usually begins in cells that turn into white ...